UroGen Pharma

$20.38
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.35 (-1.69%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell UroGen Pharma and other stocks, options, and ETFs commission-free!

About URGN

UroGen Pharma Ltd. Ordinary Shares, also called UroGen Pharma, is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. It has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. The firm's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen's approved product, Jelmyto (mitomycin) for pyelocalyceal solution, and investigational treatment UGN-102 (mitomycin) for intravesical solution, are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade non-muscle invasive bladder cancer, respectively. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ. The listed name for URGN is UroGen Pharma Ltd. Ordinary Shares.

CEO
Elizabeth Barrett
Employees
173
Headquarters
Princeton, New Jersey
Founded
2004
Market Cap
450.26M
Price-Earnings Ratio
Dividend Yield
Average Volume
132.85K
High Today
$20.70
Low Today
$19.94
Open Price
$20.61
Volume
201.42K
52 Week High
$35.21
52 Week Low
$13.12

Collections

URGN Earnings

-$1.86
-$1.24
-$0.62
-$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 1, Pre-Market

You May Also Like